Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination

Annals of Neurology

Volumn 47, Issue 6, 2000, Pages 707-717

  Lucchinetti, Claudia ^a   Brück, Wolfgang ^a   Parisi, Joseph ^b   Scheithauer, Bernd ^d   Rodriguez, Moses ^a   Lassmann, Hans ^c  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF VIENNA   (Austria)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL FEATURE; DEMYELINATING DISEASE; DISEASE ACTIVITY; DISEASE COURSE; HUMAN; HUMAN TISSUE; MULTIPLE SCLEROSIS; OLIGODENDROGLIA; PATHOGENESIS; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AUTOPSY; BIOPSY; BRAIN; CHILD; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN SHEATH; OLIGODENDROGLIA; T-LYMPHOCYTES;

EID: 0342906187     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q     Document Type: Article

References (45)

1. Ebers GC, Kukay K, Bulman DE, et al. A full genomic search in multiple sclerosis. Nat Genet 1996;13:472-476
2. Haines JL, Ter-Minassian M, Bazyk A, et al. A genomic screen for multiple sclerosis underscores a role for the major histocompatibility complex. The Multiple Sclerosis Genetics Group. Nat Gen 1996;13:469-471
3. Sawcer S, Jones HB, Feakes R, et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet 1996;13:469-471
4. Ebers G. Natural history of multiple sclerosis. In: Compston A, ed. McAlpine's multiple sclerosis. 3rd ed. London: Churchill Livingstone, 1998:191-222
5. Compston A. Genetic susceptibility to multiple sclerosis. In: Compston A, ed. McAlpine's multiple sclerosis. 3rd ed. London: Churchill Livingsrone, 1998:101-142
6. Lee MA, Smith S, Palace J, et al. Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in MS: evidence for distinct mechanisms of lesion genesis? Brain 1999;122:1261-1270
7. Ulvestad E, Williams K, Vedeler C, et al. Reactive microglia in multiple sclerosis lesions have an increased expression of receptors for the Fc part of IgG. J Neurol Sci 1994;121:125-131
8. Sriram S, Rodriguez M. Indictment of microglia as the villain in multiple sclerosis. Neurology 1997;48:464-470
9. Brück W, Porada P, Poser S, et al. Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995;38:788-796
10. Hofman FM, Hinton DR, Johnson K, Merrill JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989;170:607-612
11. Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 1991;87:949-954
12. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin of the central nervous system. Cell 1996; 85:299-302
13. Bagasra O, Michaels FH, Zheng YM, et al. Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci USA 1995;92: 12041-12045
14. Prineas JW, Graham JS. Multiple sclerosis: capping of surface immunoglobulin G on macrophages engaged in myelin breakdown. Ann Neurol 1981;10:149-158
15. Storch MK, Piddlesden S, Haltia M, et al. Multiple sclerosis: in situ evidence for antibody and complement mediated demyelination. Ann Neurol 1998a;43:465-471
16. Gay FW, Drye TJ, Dick GW, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis: identification and characterization of primary demyelinating lesion. Brain 1997;120:1461-1483
17. Genain CP, Cannella B, Hauser SL, Raine CS. Autoantibodies to MOG mediate myelin damage in MS. Nat Med 1999;5: 170-175
18. Itoyama Y, Sternberger NH, Webster H deF, et al. Immunocytochemical observations on the distribution of myelin-associated glycoprotein and myelin basic protein in multiple sclerosis lesions. Ann Neurol 1980;7:167-177.
19. Rodriguez M, Scheithauer BW: Ultrastructure of multiple sclerosis. Ultrastruct Pathol 1994;18:3-13
20. Ozawa K, Suchanek G, Breitschopf H, et al. Patterns of oligodendroglia pathology in multiple sclerosis. Brain 1994;117: 1311-1322
21. Lucchinetti CL, Bruck WB, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathology 1996;6:259-274
22. Vass K, Lassmann H, Wekerle H, Wisniewski HM. The distribution of Ia-antigen in the lesions of rat acute experimental allergic encephalomyelitis. Acta Neuropathol (Berl) 1986;70: 149-160
23. Breitschopf H, Suchanek G, Gould RM, et al. In situ hybridization with digoxigenin-labeled probes: sensitive and reliable detection method applied to myelinating rat brain. Acta Neuropathol 1992;84:581-587
24. Gold R, Schmied M, Giegerich G, et al. Differentiation between cellular apoptosis and necrosis by combined use of in situ tailing and nick translation techniques. Lab Invest 1994;71: 219-225
25. Rindfleisch E. Histologisches Detail zur grauen Degeneration von Gehirn und Rückenmark. Arch Pathol Anat Physiol Klin Med (Virchow) 1863;26:474-483
26. Dawson JW. The histology of disseminated sclerosis. Trans R Soc 1916;50:517-540
27. Bonetti B, Raine CS. Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann Neurol 1997;42:74-84
28. Linington C, Bradl M, Lassmann H, et al. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/ oligodendrocyte glycoprotein. Am J Pathol 1988;130:443-454
29. Storch MK, Stefferl A, Brehm U, et al. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol 1998b;8:681-694
30. Sahrbacher UC, Lechner F, Eugster HP, et al. Mice with an inactivation of the inducible nitric oxide synthase gene are susceptible ro experimental autoimmune encephalomyelitis. Eur J Immunol 1998;28:1332-1338
31. Itoyama Y, Webster H deF, Sternberger NH, et al. Distribution of papovavirus, myelin-associated glycoprotein, and myelin basic protein in progressive multifocal leukoencephalopathy lesions. Ann Neurol 1982;11:396-407
32. Itoyama Y, H deF Webster. Immunocytochemical study of myelin-associated glycoprotein and basic protein in acute experimental allergic encephalomyelitis (EAE). J Neuroimmunol 1982;3:351-364
33. Winchell KH, Sternberger NH, Webster H deF. Myelin-associated glycoprotein localized immunocytochemically in peroaxonal regions of oligodendroglia during hexachlorophene intoxication. Brain Res 1982;239:679-684
34. Trapp BD, Quarles RH. Immunocytochemical localization of the myelin-associated glycoprotein. J Neuroimmunol 1984;6: 231-249
35. Trapp BD. Myelin-associated glycoprotein: location and potential functions. Ann NY Acad Sci 1990;605:29-43
36. Gendelman HE, Pezeshkpour GH, Pressman NJ, et al. A quantitation of myelin-associated glycoprotein and myelin basic protein loss in different demyelinating diseases. Ann Neurol 1985; 18:324-329
37. Prineas JW, Kwon EE, Sternberger NH, Lennon VA. The distribution of myelin-associated glycoprotein and myelin basic protein in actively demyelinating multiple sclerosis lesions. J Neuroimmunol 1984;6:251-264
38. Ludwin SK, Johnson ES. Evidence of a "dying-back" gliopathy in demyelinating disease. Ann Neurol 1981;9:301-305
39. Rodriguez M: Virus-induced demyelination in mice: "dying-back" of oligodendrocytes. Mayo Clin Proc 1995;60:433-438
40. Lassmann H, Bartsch U, Montag D, Schachner M. Dying-back oligodendrogliopathy: a late sequel of myelin-associated glycoprotein deficiency. Glia 1997;19:104-110.5
41. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983:227-231
42. Radzun HJ, Hansmann ML, Heidebrecht HJ, et al. Detection of a monocyte/macrophage differentiation antigen in routinely processed paraffin-embedded tissues by monoclonal antibody Ki-M1P. Lab Invest 1991;65:306-315
43. Dobersen MJ, Hammer JA, Noronha AB, et al. Generation and characterization of mouse monoclonal antibodies to myelin-associated glycoprorein (MAG). Neurochem Res 1985;10:499-513
44. Matthieu J-M, Amiguet P. Myelin/oligodendrocyte glycoprotein expression during development in normal and myelin-deficient mice. Dev Neurosci 1990;12:293-302
45. Piddlesden S, Lassmann H, Zimprich F, et al. The demyelinating potential of antibodies to myelin oligodendroglia glycoprotein is related to their ability to fix complement. Am J Pathol 1993;143:555-564